Quote:

---

This paper about Long Covid was published yesterday and mentions Leronlimab. It's crazy our little drug isn't being researched further for this urgent indication.

---

The complement pathway mentioned in the article is associated with the CCR5 receptor and it's chemokines. The first step in the complement pathway is DAMPS (danger-associated molecular patterns) or PAMPS (pathogen-associated molecular patterns) released by damaged cells in response to viruses, bacteria or other damage binding to toll like and other receptors. This then activates complement pathway binding of the C factors mentioned in the article which induces antigens and increases inflammatory and reactive chemokines and their associated receptors including CCR5.

The increase of those receptors and chemokines then increases complement activation in a feedback loop. The chemokines and receptors themselves have feedback loops that increase each other. It's when the chemokine/receptor feedback loops get out of control and overwhelm anti-inflammatory chemokines where the real problems start and the destruction begins.

Why not target the complement pathway or PAMPS and DAMPs themselves rather than downstream factors like CCR5? Because you'd compromise the immune system quite badly.